Home About Science Investors & Partners Our people News & Events Careers Contact us Artios: Defining next generation DDR medicines We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to specifically destroy certain devastating cancers that are difficult to treat. Artios doses first patient with Polθ Inhibitor ART4215 Click Here Artios - Targeting DDR First-in-Class Developed by an expert team Targeting DDR Taking control of the DNA Damage Response Latest News Listen to our CEO and CSO talk at the Northland Synthetic Lethality Conference – Nov 17 2021 December 2, 2021 CONFERENCES Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair November 16, 2021 PRESS RELEASE Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215 September 28, 2021 PRESS RELEASE View all Quick links Home About Science Our team News & events Contact us Contact Telephone: +44 (0)1223 867 900 General enquiries: info@artiospharma.com Careers: HR@artiospharma.com Finance: Accounts@artiospharma.com Our career opportunities Our careers © Artios Pharma 2019 Terms & conditions | Privacy policy | Site map We use cookies to collect data, please see our privacy policy.